Related Experiment Video

Updated: Jan 22, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

363

Treatment of Non-small Cell Lung Cancer with EGFR-mutations

Kazue Yoneda1, Naoko Imanishi1, Yoshinobu Ichiki1

  • 1Second Department of Surgery (Chest Surgery), School of Medicine, University of Occupational and Environmental Health, Japan.

Journal of UOEH
|July 12, 2019
PubMed

Insights

Activating mutations in the epidermal growth factor receptor (EGFR) gene have shifted non-small cell lung cancer (NSCLC) treatment. EGFR tyrosine kinase inhibitors (TKIs) offer superior survival benefits for advanced NSCLC with EGFR mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Activating mutations in the epidermal growth factor receptor (EGFR) gene are key drivers in non-small cell lung cancer (NSCLC).
  • Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have revolutionized NSCLC treatment, particularly for patients with activating EGFR mutations.
  • The development of more potent and selective EGFR-TKIs, including irreversible inhibitors, aims to further improve therapeutic outcomes.

Purpose of the Study:

  • To review the current treatment strategies for EGFR-mutated NSCLC.
  • To discuss the efficacy and safety of various EGFR-TKIs.
  • To explore future perspectives in the management of EGFR-mutated NSCLC.

Main Methods:

  • Review of clinical trials and scientific literature on EGFR-TKI therapy in NSCLC.
  • Analysis of treatment outcomes, including survival benefits and toxicity profiles.
  • Discussion of ongoing research in neoadjuvant and adjuvant settings for early-stage NSCLC.

Main Results:

  • EGFR-TKIs are preferred over platinum-based chemotherapy for advanced NSCLC with activating EGFR mutations, offering superior survival.
  • Irreversible EGFR-TKIs, such as osimertinib, demonstrate improved survival benefits and reduced toxicity.
  • Combination therapies (EGFR-TKI plus chemotherapy) show potential for long-term survival.
  • Clinical trials are evaluating EGFR-TKIs in earlier stages of NSCLC (neoadjuvant and adjuvant settings).

Conclusions:

  • EGFR-TKIs represent a cornerstone in the treatment of EGFR-mutated NSCLC.
  • Advancements in EGFR-TKI development and combination strategies offer promising therapeutic options.
  • Ongoing research in early-stage disease holds potential for further improving patient outcomes.
Keywords:
activating mutationepidermal growth factor receptor (EGFR)lung cancerresistance mutationtyrosine kinase inhibitor (TKI)

More Related Videos

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

9.2K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.2K

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.6K
Mutations01:39

Mutations

Overview
94.4K
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
44.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Viral Mutations00:36

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K
Mutation, Gene Flow, and Genetic Drift01:09

Mutation, Gene Flow, and Genetic Drift

In a population that is not at Hardy-Weinberg equilibrium, the frequency of alleles changes over time. Therefore, any deviations from the five conditions of Hardy-Weinberg equilibrium can alter the genetic variation of a given population. Conditions that change the genetic variability of a population include mutations, natural selection, non-random mating, gene flow, and genetic drift (small population size).
63.1K